Table 1.
Variable | Univariate regression analysis | Multivariate model* (B=4.075, R2=0.101) | |||||
B | 95% CI for B | P value | R2 | B | 95% CI for B | P value | |
PCOS | NA | NA | NA | NA | −0.087 | −0.190 to 0.016 | 0.099 |
BMI 14 years | −0.011 | −0.022 to 0.000 | 0.057 | 0.002 | |||
BMI 31 years | −0.022 | −0.028 to −0.016 | <0.001 | 0.022 | |||
BMI 46 years | −0.028 | −0.033 to −0.023 | <0.001 | 0.055 | −0.007 | −0.016 to 0.002 | 0.140 |
Waist circumference | −0.012 | −0.014 to −0.010 | <0.001 | 0.061 | |||
Systolic BP | −0.007 | −0.009 to −0.005 | <0.001 | 0.032 | |||
Diastolic BP | −0.015 | −0.017 to −0.013 | <0.001 | 0.066 | |||
Mean arterial pressure | −0.012 | −0.014 to −0.010 | <0.001 | 0.054 | −0.007 | −0.011 to −0.004 | <0.001 |
Testosterone | 0.042 | −0.010 to 0.093 | 0.113 | 0.001 | |||
SHBG | 0.001 | 0.001 to 0.002 | <0.001 | 0.005 | |||
FAI | −0.121 | −0.199 to −0.042 | 0.003 | 0.003 | 0.059 | −0.055 to –0.173 | 0.309 |
Glucose | −0.121 | −0.153 to −0.089 | <0.001 | 0.023 | |||
Insulin | −0.014 | −0.018 to −0.011 | <0.001 | 0.027 | |||
HOMA-IR | −0.492 | −0.585 to −0.399 | <0.001 | 0.049 | −0.256 | −0.420 to −0.092 | 0.002 |
Total cholesterol | −0.067 | −0.096 to −0.038 | <0.001 | 0.009 | |||
High-density lipoprotein | 0.138 | 0.076 to 0.201 | <0.001 | 0.008 | |||
Low-density lipoprotein | −0.086 | −0.114 to −0.058 | <0.001 | 0.015 | |||
Triglycerides | −0.243 | −0.285 to −0.200 | <0.001 | 0.050 | −0.341 | −0.558 to −0.123 | 0.002 |
High-sensitive CRP | −0.071 | −0.084 to −0.057 | <0.001 | 0.034 | |||
Anxiety (HSCL-25) | −0.195 | −0.274 to −0.117 | <0.001 | 0.010 |
*The multivariate model included PCOS, BMI, mean arterial pressure, FAI, HOMA-IR and triglycerides as explanatory variables. B, unstandardized coefficient from linear regression analysis.
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; FAI, free androgen index; HOMA-IR, homeostasis model assessment−insulin resistance; NA, not applicable; PCOS, polycystic ovary syndrome; rMSSD, the square root of the mean squared differences of successive normal-to-normal RR intervals (RRi); SHBG, sex hormone binding globulin.